Skip to main content

Table 1 Distribution of the patient characteristics/potential prognostic factors in both treatment groups

From: A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases

 

WBRT + stereotactic boost

(n = 84)

N patients (%)

WBRT alone

(n = 168)

N patients (%)

Fractionation of WBRT

 5 x 4 Gy (n = 33)

11 (13)

22 (13)

 Longer-course WBRT (n = 219)

73 (87)

146 (87)

Age at WBRT

 ≤58 years (n = 132)

44 (52)

88 (52)

 ≥ 59 years (n = 120)

40 (48)

80 (48)

Gender

 Female (n = 150)

50 (60)

100 (60)

 Male (n = 102)

34 (40)

68 (40)

Karnofsky performance score

 70 (n = 78)

26 (31)

52 (31)

 ≥80 (n = 174)

58 (69)

116 (69)

Type of primary tumor

 Breast cancer (n = 69)

23 (27)

46 (27)

 Lung cancer (n = 156)

52 (62)

104 (62)

 Other cancers (n = 27)

9 (11)

18 (11)

Number of cerebral metastases

 1 (n = 120)

40 (48)

80 (48)

 2-3 (n = 132)

44 (52)

88 (52)

Extracerebral metastases

 No (n = 114)

38 (45)

76 (45)

 Yes (n = 138)

46 (55)

92 (55)

RPA class

 Class 1 (n = 90)

30 (36)

60 (36)

 Class 2 (n = 162)

54 (64)

108 (64)

Interval from cancer diagnosis to WBRT

 ≤ 15 months (n = 120)

40 (48)

80 (48)

 ≥ 16 months (n = 132)

44 (52)

88 (52)